# A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects

> **NCT04818229** · PHASE1 · COMPLETED · sponsor: **Connect Biopharma Australia Pty Ltd** · enrollment: 112 (actual)

## Conditions studied

- Autoimmune Diseases

## Interventions

- **DRUG:** CBP-307
- **DRUG:** Placebo-matched CBP-307
- **DRUG:** Moxifloxacin (Avelox)
- **DRUG:** Placebo-matched Moxifloxacin

## Key facts

- **NCT ID:** NCT04818229
- **Lead sponsor:** Connect Biopharma Australia Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-01
- **Primary completion:** 2022-03-20
- **Final completion:** 2022-03-30
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2024-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04818229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04818229, "A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04818229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*